Siste oppdatering :
14/12/2024
kreft narkotika   Vinorelbine tartrate  
Injeksjon
Oppløsningsstabilitet Stabilitet i blandinger Faktorer som påvirker stabiliteten Kompatibilitet Administrasjonsmåte Referanser pdf
   Kjemisk struktur  

Handelsnavn   Handelsnavn     

Handelsnavn er veiledende og sammensetning av hjelpestoffer kan være forskjellig avhengig av land og produsent

Eberelbin Iran
Eunexon Peru
Eurovinorelbin Tyskland
Navelbin Ungarn
Navelbine Argentina, Australia, Belgia, Chile, Colombia, Danmark, De forente arabiske emirater, Egypt, Finland, Frankrike, Hellas, India, Iran, Irland, Island, Italia, Luxembourg, Malaysia, Mexico, New Zealand, Norge, Peru, Polen, Portugal, Romania, Saudi-Arabia, Spania, Storbritannia, Sveits, Sverige, Tunisia, Tyrkia, Tyskland, USA, Østerrike
Navildez Mexico
Navin Tyskland
Navirel Norge, Sverige, Tyskland
Okabine Peru
Relbinalur Sverige
Renovel Tyrkia
Setroxin Mexico
Sulcoline Argentina
Tarckorel Mexico, Peru
Vieby Mexico
Viessia Colombia, Mexico, Venezuela
Vilne Argentina, Ecuador, Peru
Vinarine Argentina, Peru, Venezuela
Vinelbine Malaysia
Vinilex Mexico
Vinkebir Argentina, Peru
Vinobina Colombia
Vinobur Sverige
Vinolbin Tyskland
Vinorel Argentina, Peru
Vinorelbin Belgia, Ecuador, Island, Norge, Romania, Sveits, Sverige, Tyskland, Østerrike
Vinorelbina Colombia, Ecuador, Mexico, Peru, Romania, Spania
Vinorelbine Argentina, Belgia, Canada, Iran, New Zealand, Storbritannia, Sveits, USA
Vinorgen Chile, Peru
Zinavin Colombia
Referanser   Injeksjon   Referanser : Vinorelbine tartrate  
Type publikasjon
84 Journal Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
144 Journal Dine T, Luyckx M, Cazin JC, Goudaliez F, Mallevais ML.
Stability and compatibility studies of vinblastine, vincristine, vindesine and vinorelbine with PVC infusion bags.
Int J Pharm 1991 ; 77: 279-285.
182 Journal Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
244 Journal Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
251 Journal Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
307 Journal Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
905 Journal Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 Journal Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1070 Journal Balthasar JP.
Concentration-dependent incompatibility of vinorelbine tartrate and heparin sodium.
Am J Health-Syst Pharm 1999 ; 56: 1891.
1413 Journal Lieu CL, Chin A, Gill MA.
Five-day stability of vinorelbine in 5% dextrose injection and in 0.9% sodium chloride injection at room temperature.
Int J Pharm Compound 1999 ; 3: 67-68.
1423 Journal Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1501 Journal Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M.
Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials.
Int J Pharm 1999 ; 185: 113-121.
1520 Labratorium Etude de stabilité des médicaments en Ecoflac®
B Braun 2001
1625 Journal Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1662 Journal Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
2260 Labratorium Stability of vinorelbin "Ebewe" infusion solutions.
Ebewe Pharma 2007
3128 Labratorium Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit
Prostrakan 2013
3474 Labratorium Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009
3595 Labratorium Aciclovir - Summary of Product Characteristics
Hospira 2009
3641 Labratorium Vinorelbine (Navelbine®) - Summary of Product Characteristics
Pierre Fabre 2011
3644 Labratorium Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3838 Labratorium Magnesium Sulphate - Summary of Product Characteristics
Martindale Pharmaceuticals Ltd 2007
4471 Labratorium Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019
Kyowa Kirin Pharma 2019

  Mentions Légales